Creating Value by Overcoming Treatment Barriers View previous quarters - Today Latest News View all press releases 03.30.26 Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film Read More 03.20.26 Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer Read More 03.09.26 Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4) Read More Events View all events Upcoming Events There are no scheduled events at this time. Past Events 03.10.26 8:25 AM EDT Citizens Life Sciences Conference 03.09.26 10:40 AM EDT Leerink Partners Global Healthcare Conference 2026 Presentations View all presentations Corporate Presentation – February 2026 Anaphylm™ (dibutepinephrine) Sublingual Film Complete Response Letter Supplemental Material 1.1 MB Anaphylm Pre-NDA Meeting Supplemental Material 525.4 KB
03.30.26 Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film Read More
03.20.26 Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer Read More
03.09.26 Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4) Read More
